Article Text
PDF
Abstract
Introduction/Background SUROVA study focuses on consecutive cases of ovarian cancer operated on in 2018 and 2019 in hospitals worldwide that meet the inclusion and exclusion criteria. We plan to balance both groups through a Matched Propensity Score Cohort Study, Inverse Probability Weighting, and Artificial Intelligence for variables showing statistical significance in univariate and multivariate analysis.
The main objective is to compare 5-year Overall Survival in patients undergoing primary cytoreductive surgery versus neoadjuvant chemotherapy and interval cytoreductive surgery for stage IIIB-IVB ovarian cancer. Secondary objectives include 5-year Progression-Free Survival, time to the first and second subsequent anticancer treatment or death, collecting information on surgical treatment approaches and decision-making processes for patients with advanced high-grade ovarian cancer worldwide, expanding surgery according to Aletti’s surgical complexity score, documenting surgical complications, and comparing outcomes between patients with BRCA mutations and those without this mutation, as well as between patients with Homologous Recombination DNA Repair (HRD) deficiency and those with HRD competence.
Methodology Primary endpoint
Compare overall survival (OS) at 5 years in patients who underwent primary cytoreductive surgery vs. neoadjuvant chemotherapy and interval cytoreductive surgery for stage IIIB-IVB ovarian cancer.
Secondary endpoints
Progression Free Survival (PFS) at 5 years.
Time to first and second subsequent anticancer therapy or death.
Compare the outcomes between patients with BRCA mutations and those without this mutation.
Compare the outcomes between patients with HRD deficiency and those with HRD proficiency.
Results A total of 280 centers in 71 countries have already committed to participating in the study, so we expect an estimated sample size of 10,000 patients.
Conclusion If the study is successful and expectations are met, it will be the largest cross-sectional study ever to collect data on ovarian cancer.’
Disclosures No disclosures.
